Ethinyl Estradiol Estrogen/progestogen Receptor agonist

Cat.No.S1625

Ethinyl Estradiol is an orally bio-active estrogen used in almost all modern formulations of combined oral contraceptive pills.
Ethinyl Estradiol Estrogen/progestogen Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 296.4

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 296.4 Formula

C20H24O2

Storage (From the date of receipt)
CAS No. 57-63-6 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O

Solubility

In vitro
Batch:

DMSO : 59 mg/mL (199.05 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 59 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
Estrogen receptor [1]
In vitro
Ethinyl Estradiol increases respiratory chain activity in both cultured rat hepatocytesand HepG2 cells. This compound is a strong promoter of hepatocarcinogenesis. [1] It enhances the transcript levels of nuclear genome- and mitochondrial genome-encoded genes and respiratory chain activity in female rat liver, and also inhibits transforming growth factor beta (TGFbeta)-induced apoptosis in cultured liver slices and hepatocytes from female rats. This chemical increases the transcript levels of the mitochondrial genome-encoded genes cytochrome oxidase subunits I, II, and III in cultured female rathepatocytes. It significantly increases both the levels of glutathione (reduced [GSH] and oxidized [GSSG] forms) per mg protein in mitochondria and nuclei, while the percentage of total glutathione in the oxidized form is not affected. [2]
In vivo
Ethinyl Estradiol (50 mg/kg/day) increases anogenital distance and reduces pup body weight at postnatal day 2, accelerates the age at vaginal opening, reduces F1 fertility and F2 litter sizes, and induces malformations of the external genitalia (5 mg/kg) in the female Long-Evans rat. [3] This compound increases the number of low density lipoprotein (LDL) receptors in livers of rats, thereby producing a profound fall in plasma cholesterol levels. It exerts the same effect in livers of male and female rabbits and that the increase in receptor number is correlated with a 6- to 8-fold increase in the levels of receptor mRNA. [4]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06380205 Recruiting
Healthy Participants
Incyte Corporation
May 7 2024 Phase 1
NCT06334315 Not yet recruiting
Contraception|Pharmacogenomic Drug Interaction
Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
May 2024 Phase 4
NCT06039826 Active not recruiting
Overweight
Eli Lilly and Company
September 12 2023 Phase 1
NCT05671653 Terminated
Obesity
Pfizer
January 19 2023 Phase 1
NCT05360550 Completed
Pregnancy Prevention
Lupin Research Inc
July 5 2022 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map